3 results
Approved WMORecruiting
To determine the effect of lithium treatment (plasma levels between 0,4-0,8 mEq/liter) versus placebo - in addition to riluzole 2dd 50 mg - on reaching a clinical endpoint in patients with ALS.
Approved WMORecruiting
Objectives of Part A, B and C are the following: Part A: determination of the optimal mass dose of S095012 to inject with 89Zr-S095012 and optimal time point for PET scans for appropriate visualisation of 89Zr-S095012 through PET imaging. Part B…
Approved WMORecruiting
To investigate the efficacy and safety of drugs for patients with ALS.